Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
BioMarin Pharmaceuticals, Inc. (NQ: BMRN)
57.21 USD  UNCHANGED
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 19, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about BioMarin Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
June 14, 2013
Editor Note: For more information about this release, please scroll to bottom. Read More
from PR Newswire
UPDATE: Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs Global Healthcare Conference
June 06, 2013
from GlobeNewswire News Releases
BioMarin to Present at the Goldman Sachs Global Healthcare Conference
June 06, 2013
from GlobeNewswire News Releases
Critical Alerts For General Motors, SAP, Blackberry, BioMarin Pharmaceutical, and Trimble Navigation Released By InvestorsObserver
June 05, 2013
from PR Newswire
BioMarin Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU
June 05, 2013
from GlobeNewswire News Releases
BioMarin Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting
June 03, 2013
Phase 3 Trial in Metastatic gBRCA Breast Cancer Planned to Start in Q4 2013 Read More
from GlobeNewswire News Releases
BioMarin to Present at the Jefferies Global Healthcare Conference
May 30, 2013
from GlobeNewswire News Releases
FDA Accepts Vimizim BLA and Grants Priority Review Designation
May 30, 2013
PDUFA Action Date Extended to February 28, 2014 Read More
from GlobeNewswire News Releases
Vimizim MAA Validated by the EMA
May 30, 2013
Vimizim Designated for Accelerated Assessment by the EMA Read More
from GlobeNewswire News Releases
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 20, 2013
from GlobeNewswire News Releases
BioMarin Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at ASCO
May 16, 2013
Phase 3 Trial in gBRCA Breast Cancer Planned for 4Q 2013 Read More
from GlobeNewswire News Releases
BioMarin to Present at the UBS Global Healthcare Conference
May 14, 2013
from GlobeNewswire News Releases
BioMarin to Present at the Baird Growth Stock Conference
May 02, 2013
from GlobeNewswire News Releases
BioMarin Announces First Quarter 2013 Financial Results
April 25, 2013
from GlobeNewswire News Releases
BioMarin Submits Vimizim MAA to EMA for the Treatment of MPS IVA
April 24, 2013
from GlobeNewswire News Releases
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 18, 2013
from GlobeNewswire News Releases
Pre-Market Analysis on Sarepta Therapeutics, BioMarin Pharma, Theravance, and Chelsea Therapeutics
April 08, 2013
from PR Newswire
BioMarin to Host First Quarter 2013 Financial Results Conference Call and Webcast on Thursday, April 25 at 5:00 p.m. ET
April 04, 2013
from GlobeNewswire News Releases
BioMarin Submits CTA for BMN-190 for Batten Disease
April 01, 2013
from GlobeNewswire News Releases
BioMarin Submits Vimizim BLA to the U.S. FDA for the Treatment of MPS IVA
April 01, 2013
from GlobeNewswire News Releases
BioMarin Completes Additional Partial Exchange of Convertible Notes Due 2017 for Common Stock
March 25, 2013
from GlobeNewswire News Releases
BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Development
March 19, 2013
from GlobeNewswire News Releases
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
March 19, 2013
from GlobeNewswire News Releases
BioMarin Completes Partial Exchange of Convertible Notes Due 2017 for Common Stock
March 18, 2013
from GlobeNewswire News Releases
Innovative Product Portfolios Ride Commercialization & Global Expansion - Research Report on Amgen, Onyx Pharmaceuticals, Alexion Pharmaceuticals, BioMarin Pharmaceutical and Incyte
March 18, 2013
from PR Newswire
BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review
March 07, 2013
from PR Newswire
BioMarin to Attend Upcoming Conferences: Cowen Healthcare Conference, Credit Suisse Global Healthcare Conference and Barclays Global Healthcare Conference
February 28, 2013
from GlobeNewswire News Releases
BioMarin Announces Fourth Quarter and Full Year 2012 Financial Results
February 21, 2013
from GlobeNewswire News Releases
BioMarin Licenses Factor VIII Gene Therapy Program for Hemophilia A From University College London and St. Jude Children's Research Hospital
February 21, 2013
from GlobeNewswire News Releases
BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 20, 2013
from GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here